Best Healthcare Companies in Gaithersburg, United States
The 35 best Healthcare companies in Gaithersburg, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Euclid Techlabs.
Ranked: Best Healthcare companies in Gaithersburg
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Euclid Techlabs Developer of compact accelerators and diamond materials for diverse applications | $73M | 17 mo ago | Funding Raised | — | 2003 | WordPressMySQLPHP+18 | 25 patents Patents concentrated in electrical & electronics | — |
| 2 | GlycoMimetics Small molecule therapeutics to mimic the functions of bioactive carbohydrates | $39M | 190 mo ago | Acquired | — | 2003 | DrupalPHPAmazon Web Services+20 | 402 patents Patents concentrated in chemistry & materials | — |
| 3 | Salubris Biotherapeutics Developer of antibody therapeutics for the treatment of cancer, cardiovascular and metabolic diseases | $35M | 28 mo ago | Series A | — | 2016 | — | 60 patents Patents concentrated in chemistry & materials | — |
| 4 | Cerium CRO focusing on developing and commercialising of drugs for the treatment of orphan diseases | $11M | 61 mo ago | Series A | Gregg Lapointe Co-Founder & CEO | 2012 | — | — | — |
| 5 | Propagenix Cell models and cell-based therapies using its Conditional Replication (CR) technology | $9M | 68 mo ago | Acquired | — | 2014 | — | 48 patents Methods for ex vivo expansion of epithelial cells for regenerative medicine | — |
| 6 | DFH Pharma Developer of pharmaceutical products, focusing on drug development and medical trends | $2M | 11 mo ago | Funding Raised | Carl Wild Founder & CEO | 2011 | — | — | — |
| 7 | MedImmune Biologic R&D for oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases | $2M | 96 mo ago | Acquired | Speck Loe CEO | 1987 | — | 3,933 patents Engineered therapeutic antibodies and bispecifics for immune modulation and targeted drug delivery | — |
| 8 | Adventist HealthCare Standalone multi speciality hospital | $2M | 39 mo ago | Funding Raised | Terry Forde CEO & President | 1907 | SentryApple iCloud MailGoogle Maps+21 | — | 1 award |
| 9 | Capital Biosciences Provider of cell and molecular biology-based products and services | $150K | 149 mo ago | Funding Raised | Gary Veytsman Founder & CEO | 2006 | — | — | — |
Top 9 Healthcare companies in Gaithersburg
#1
Funding Raised · Gaithersburg, Maryland · founded 2003 · 25 employees$72.7Mraised▾
Developer of compact accelerators and diamond materials for diverse applications. It provides ultrafast electron microscopy upgrades, portable MeV range electron sources for various uses including medical radiotherapy and security screening, and high-quality lab-grown diamonds for optical and electronic applications. The company also offers accelerator components and services to research institutions and industries, along with custom solutions and consulting. Data management software complements its hardware offerings.
- Mar 2025Grant (prize money)$1.4M
- Sep 2023Grant (prize money)$200K
- Jul 2023Grant (prize money)$206.5K
- Jun 2021Grant (prize money)$811.7K
#2
Funding Raised · Gaithersburg, Maryland · founded 2011$2.3Mraised▾
Developer of pharmaceutical products, focusing on drug development and medical trends. The company strives to improve patient health within the healthcare industry. Its team monitors medical advancements and technology. The company focuses on finding better methods in an evolving industry.
- Sep 2025Grant (prize money)$986.9K
- Jul 2020Grant (prize money)$943.1K
- Sep 2018Grant (prize money)$171.5K
- Aug 2013Grant (prize money)$186.4K
#3
Series A · Gaithersburg, Maryland · founded 2016 · 1 employees$35Mraised▾
Salubris Biotherapeutics (SalubrisBio) is a biotechnology company (part of Shenzhen salubris pharmaceuticals) developing antibody and protein-based therapeutics for the treatment of cancer, cardiovascular and metabolic diseases. Their lead candidate (undisclosed) is in the preclinical stage. It used to treat cancer.
- Apr 2024Series A$35M
#4
Acquired · Gaithersburg, Maryland · founded 2003 · 39 employees$39Mraised▾
GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin. It has been shown in a Phase 2 clinical study to have the potential to provide a treatment for vaso-occlusive crisis of sickle cell disease; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.
- Oct 2010Series C$39M
- Jun 2009Grant (prize money)$350.3K
- Jun 2009Grant (prize money)$350.3K
#5
Series A · Gaithersburg, Maryland · founded 2012 · 3 employees$11.2Mraised▾
Developer of drugs for rare diseases designed to focus on the development of medicines for efficacious therapies for patients with unmet needs. The company's drugs helps to cure pediatric and ultra-orphan conditions with high therapeutic value, enabling patients of special categories to cure the ailment without any harmful side effects.
- Jul 2021Series A$8.9M
- May 2021Conventional Debt$1.9M
- Jun 2016Seed$2.3M
#6
Acquired · Gaithersburg, Maryland · founded 2014 · 5 employees$8.8Mraised▾
Propagenix is an R&D-stage cell therapy company engaged in the development of the primary cells, tumor cell models and cell therapies. It is currently focussed on continuing the development of Conditional Replication (CR) technology that generates unlimited quantities of biologically important cell types ex vivo that retain the ability to re-adopt the relevant functionality of the tissues from which the cells originated. It has developed multiple human and other mammalian cell cultures and stable cell lines from tumor cells. Besides, it has a set of cell therapy preclinical-stage programs related to pancreatic diseases, autologous skin engraftment and airway injury and respiratory diseases.
- Jan 2021Grant (prize money)$182.8K
- Sep 2018Grant (prize money)$263.2K
- May 2017Grant (prize money)—
- May 2017Grant (prize money)$225K
#7
Funding Raised · Gaithersburg, Maryland · founded 1907 · 2695 employees$1.5Mraised▾
Standalone multi speciality hospital
- 2023Grant (prize money)$500K
- 2023Grant (prize money)$1M
#8
Acquired · Gaithersburg, Maryland · founded 1987 · 3000 employees$2.2Mraised▾
MedImmune is a global biologic R&D company developing product candidates for three therapeutic areas namely oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic disease. It was founded as Molecular Vaccines and has developed Flumist, a nasal spray influenza vaccine which was approved by FDA as a needle-free vaccine CAIV-T in 2007. In April 2007, AstraZeneca acquired MedImmune and since then it is working as its R&D unit. In September 2009, MedImmune received approval from the U.S. FDA for its intranasal novel H1N1 influenza vaccine. Currently, it claims to have more than 120 biologics in R&D and 40 products in clinical development.
- Sep 2018Grant (prize money)$354.2K
- Mar 2017Grant (prize money)$670.7K
- Jan 2017Grant (prize money)$337.3K
- Jan 2016Grant (prize money)$805.8K
#9
Funding Raised · Gaithersburg, Maryland · founded 2006 · 6 employees$150Kraised▾
Capital Biosciences Inc. is a biotechnology CRO based out of Gaithersburg, Maryland dedicated to connecting researchers from around the world with clinical sites and repositories of high-quality, clinically annotated tissue specimens, as well as custom cell and molecular biology laboratory services.
- Apr 2014Grant (prize money)$150K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.